Background Catheter-associated urinary tract infection (CAUTI) is a major preventable cause of harm for patients in hospital. We aimed to establish whether short-term routine use of antimicrobial catheters reduced risk of CAUTI compared with standard polytetrafl uoroethylene (PTFE) catheterisation.
Introduction
Urinary tract infection associated with indwelling catheters that drain urine during and after surgery or critical illness is the second most common cause of hospitalacquired infection worldwide. Conservative estimates suggest 145 000 adults were aff ected in the USA in 2010 [1] [2] [3] and 47% of newly catheterised patients in the Philippines develop such an infection. 4 Catheter-associated urinary tract infection (CAUTI) causes avoidable morbidity and increased health-care costs in high-income and developing countries. 5, 6 Implementation of evidence-based prevention strategies such as avoidance of catheter use, aseptic catheter insertion, and shortened duration of catheterisation 7, 8 have been associated with a 50% reduction in CAUTI in hospitals. 3, 9 Alternatively, catheters can be made with antimicrobial coatings that delay bacterial colonisation; two widely available examples are a silver alloy-coated latex catheter and a nitrofuralimpregnated silicone catheter, which both inhibit urin ary pathogens. 10 A Cochrane Review 11 reported that, although these devices can reduce bacterial contam ination of urine, their usefulness against symptomatic CAUTI and thus avoidance of the need for antibiotic treatment was uncertain. Recent guidance 8 called for more evidence of eff ectiveness before routine imple mentation and emphasised the need to focus on clinical outcomes such as symptomatic urinary tract infection. We aimed to establish whether short-term use of antimicrobial catheters reduced the risk of clinical CAUTI compared with equivalent use of standard catheters.
Methods

Study design and participants
In our multicentre, randomised, controlled trial, we enrolled adults (aged ≥16 years) undergoing urethral catheterisation for an anticipated duration of up to 14 days from 24 UK National Health Service (NHS) hospitals that provide surgical care in various specialties (appendix). 12 Participants who needed planned catheterisation as part of standard care were identifi ed by local researchers. Instances of unplanned catheterisation with an anticipated short duration were identifi ed by hospital ward staff . We used wide eligibility criteria, including people with diabetes and individuals treated with immunosuppressive drugs. Ineligible patients were those who had symptomatic urinary tract infection at baseline, had undergone urological procedures in the previous 7 days, or had allergies to catheter materials. Participants provided written, informed consent before randomisation apart from cases of unplanned catheterisation, in which participants were randomised and then invited to consent when recovered suffi ciently; if individuals declined to participate they were excluded from the analyses. The trial was approved by a UK NHS research ethics committee and overseen by trial steering and data monitoring committees.
Randomisation and masking
Participants were allocated through simple randomisation in a 1 Medical; control group). The randomisation was implemented with a computer generated system, which users accessed via an automated telephone service or secure website to obtain the allocation sequence. We recorded compliance with the allocated intervention. Participants, clinicians, and the trial team were not masked to the allocated intervention because of the distinctive appearances of each catheter. When the period of catheterisation was unexpectedly longer than 14 days, we recorded trial data as if the catheter had been removed on day 14.
Procedures
The primary outcome was incidence of symptomatic CAUTI, defi ned as the presence of participant-reported symptoms of urinary tract infection and clinician prescription of antibiotic for a urinary tract infection at any time up to 6 weeks after randomisation. Secondary outcomes included incidence of microbiologically confi rmed symptomatic CAUTI, which was defi ned as the primary outcome and a positive urine culture; incidence of bacteriuria up to 3 days after catheter removal; changes in health-related quality of life during the 6 weeks of trial participation; and urethral discomfort related to catheterisation. Local trial staff collected outcomes data from clinical records during hospitalisation and from self-completed participant questionnaires or diaries 3 days after catheter removal, 1-2 weeks after catheter removal, and 6 weeks after randomisation. Participant questionnaires included questions about symptoms of urinary tract infection, catheter discomfort (mild, moderate, or severe), use of antibiotics, and a generic health-related quality of life measure, EQ-5D. 13 This scale divides health status into fi ve dimensions (mobility, self care, usual activities, pain and comfort, and anxiety and depression). 13 Each of these dimensions has three levels and therefore there are 243 possible health states. We used utility scores to calculate quality-adjusted life-years by multiplying the time spent in each health state by the utility score for that state. 14 We verifi ed participant reports of an episode of CAUTI after the end of hospital visits by contacting their primary care physician to confi rm prescription of an antibiotic for urinary tract infection. Midstream voided urine samples or samples of urine taken directly from the catheter were collected at baseline, up to 3 days after catheter removal, and if feasible at the time of CAUTI. Samples were analysed according to micro biology laboratory protocols in UK NHS hospitals with a positive result defi ned as bacterial counts of 10 000 colony-forming units (cfu) per mL or more of no more than two microorganisms.
Statistical analysis
Because a high degree of benefi t would be needed to change routine clinical practice, we specifi ed a 3·3% absolute reduction on the basis of estimated incidence in the control group of 11% (30% relative reduction; odds ratio [OR] 0·67). With 90% power and 2·5% signifi cance level to account for the two comparisons, and allowing for an attrition rate of 15%, we needed to recruit 2345 participants in each group (7035 participants overall). Two comparisons of equal importance were tested in the trial: silver alloy catheters versus PTFE catheters and nitrofural catheters versus PTFE catheters. We assessed urinary tract infection outcomes with logistic regression and summarised fi ndings as absolute percentage risk diff erences and ORs, both with 95% CIs calculated as 97·5% confi dence intervals to adjust for the two comparisons. For the primary analysis, p=0·025 was regarded as signifi cant. We analysed all included participants in their allocated group irrespective of the catheter received, according to intention-to-treat principles, and assumed participants did not have a symptomatic CAUTI unless they met the primary outcome criteria. We report outcomes from an unadjusted model and an adjusted model that corrected for age, sex, comorbidities, indication for catheterisation, and antibiotic use before catheterisation. We did a sensitivity analysis with the recruiting hospital as a random eff ect. We examined the infl uence of factors that aff ect the risk of CAUTI on the reported eff ectiveness of the experimental catheters compared with control with tests for Duration of hospital admission, days 6 (3-8) 6 (3-9) 6 (3-9)
Data are mean (SD), n (%), n/number with available data (%), or median (IQR). PTFE=polytetrafl uoroethylene. CAUTI=catheter-associated urinary tract infection. cfu=colony-forming unit. *Immunosuppression was defi ned as current receipt of immunosuppressive therapy with corticosteroids, methotrexate, or chemotherapy drugs. interaction at the 1% signifi cance level because of their exploratory nature. We did a post-hoc eff ect modifi cation sensitivity analysis to explore any potential eff ects of duration of catheterisation on reported eff ectiveness. All subgroup and treatment-eff ect modifi cation analyses were done with the same generalised linear modelling framework as the main analyses. Responses to the EQ-5D were plotted as mean (SD) at 3 days, 1 week, and 2 weeks after catheter removal, and at 6 weeks after randomisation, and we assessed changes by calculating the area under the curve. We explored sensitivity to missing data with the missing at random assumption, but did not impute data. We analysed all outcomes related to symptoms and catheter-associated discomfort with ordered logit models suitable for ordinal outcome data. Analyses were done with SAS version 9.2 and Stata version 11. This study is registered, number ISRCTN75198618.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. RP, TL, GM, MK, GMc, CB, LV, and JN'D had full access to data collected for the trial, and JN'D and RP had fi nal responsibility for the decision to submit for publication.
Results
Between Adjusted odds ratio 0·96 (0·78-1·19; p=0·69) 0·99; (0·81-1·20; p=0·88)
Nitrofural vs PTFE control
Unadjusted odds ratio 0·82 (0·66-1·01; p=0·037) 0·83 (0·69-1·02; p=0·039)
Adjusted odds ratio 0·81 (0·65-1·01; p=0·031) 0·83 (0·68-1·02; p=0·045)
Data are odds ratio (95% CI; p value). PTFE=polytetrafl uoroethylene. (table 1) . We did not note any interactions between eff ectiveness of the antimicrobial catheters and presence of risk factors for CAUTI (fi gure 2). Longer catheter duration was associated with increased rate of CAUTI in all three trial groups but the statistical model showed no signifi cant interaction between catheter duration and the silver alloy versus control comparison (p=0·83) and the nitrofural versus control comparison (p=0·19; fi gure 3). Table 4 shows the time of occurrence of CAUTI relative to catheter removal. The nitrofural catheter used in the trial was associated with a reduced incidence of microbiologically proven symptomatic CAUTI (p=0·02) and a lower rate of bacteriuria (p=0·001), but also greater participant-reported discomfort during use and at removal (table 2). Health statuses did not diff er between trial groups during follow-up (table 5).
Discussion
We aimed to establish whether short-term use of either of two available antimicrobial catheters was clinically eff ective in reducing CAUTI compared with the PTFE control (panel). Interpretation of our fi ndings depends on the level of benefi t thought suffi cient to justify changes in practice. From a clinical perspective and taking into account previously reported eff ect sizes, [15] [16] [17] we regarded avoidance of one CAUTI in 30 people (3·3% absolute reduction) to be of benefi t and powered our trial accordingly. Other groups, such as patients needing short-term catheterisation or the health-care funders with a restricted budget, might have required lesser or greater degrees of benefi t.
Our best estimate of the eff ectiveness of the silver alloy catheter compared with control suggested almost no diff erence. The results suggest that 1000 people would need to receive a silver alloy catheter to prevent one CAUTI, with the true eff ect lying between one infection prevented in 42 people and one infection caused in 45 people. Because the 95% CI of the absolute risk diff erence did not include the prestated eff ect size but did include zero, we conclude that the silver alloy catheter is not eff ective for prevention of CAUTI. Nevertheless, hospitals in the USA and UK have implemented silver alloy-coated catheters for routine short-term use as part of prevention strategies against CAUTI. [17] [18] [19] This use began after a meta-analysis of previous trials suggested a relative risk of 0·54 (95% CI 0·43-0·67) for bacteriuria compared with standard catheters, 11 which was not changed substantially after accounting for possible bias. 20 We felt that bacteriuria did not match closely with the clinical diagnosis of urinary tract infection and therefore used a primary patient-reported urinary tract infection outcome backed by clinician action of antibiotic prescription without requirement for microbiological proof, assessed for at least 4 weeks after catheter removal. This analysis was designed to refl ect usual clinical care and experience of patients, with an adequate observation period to capture relevant events, and to fulfi l research priorities set out in international public health policy guide lines. 7, 21, 22 Our secondary outcomes of microbiologically proven symptomatic CAUTI and bacteriuria at up to 3 days after catheter removal were more closely matched to previous trials than was our primary analysis, but also suggested that the silver alloy catheter was 
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A B ineff ective. The early change in practice made by some hospitals was based on incomplete evidence of eff ectiveness that mainly came from underpowered studies; the contrast between the fi nding of no diff erence from a robustly designed, large, multicentre pragmatic trial, and initial promising fi ndings from smaller explanatory trials has been reported previously. 23 The best estimate of eff ectiveness for the nitrofural catheter was that they would prevent one symptomatic CAUTI in every 48 people catheterised, but that the true eff ect could lie between one in 24 people and no protective eff ect at all. This estimate was less than the eff ect size we required and the 95% CI of the absolute risk diff erence included zero so we regarded routine use of nitrofural catheters for short-term catheterisation as not clinically benefi cial. Moreover, the potential for increased discomfort, which was reported by about one in nine participants, adds to the distress of an already intimate invasive intervention. The estimate of eff ectiveness in our trial was smaller than that from meta-analyses of previous trials 8, 11 and in particular contrasts with a report 24 of a relative risk for antibiotic-treated CAUTI recorded as a secondary outcome of 0·27 (95% CI 0·10-0·69) in favour of nitrofural catheters. However, use of bacteriuria as a primary outcome and missing data for the secondary outcomes in that report 24 restricted useful comparison with our results. The contrasting lack of eff ectiveness noted in our trial might be because of our wider eligibility Our results for microbiological CAUTI and bacteriuria were suggestive of a relevant antimicrobial eff ect, but this might be off set by public health concerns about widespread use of anti microbial drugs. Nitrofuran-based antimicrobial drugs are less prone to development of bacterial resistance, 25 although we did not monitor this factor in our trial. The silicone material of manufacture might have contributed to greater antimicrobial eff ect compared with the latex control catheter, but we did not explore this because we aimed to test the eff ectiveness of the device as an available technology and thus rejected the option of inclusion of a standard silicone catheter as a second control group.
We pragmatically designed our trial to assess clinical eff ectiveness of two widely available antimicrobial catheters. We aimed to resolve uncertainty about the benefi t of antimicrobial catheters for short-term use, focusing on the clinically relevant outcome of symptomatic urinary tract infection treated with antibiotics rather than microbiologically defi ned bacteriuria. 8 We believed that our chosen primary outcome would be measurable and represent a clinically important event that shows patients' experience. This defi nition and our successful attribution of the outcome across the trial population allowed strong and practically useful conclusions to be made about the clinical eff ectiveness of antimicrobial catheters. We also adopted a pragmatic approach to recruitment, which ensured that participants were repre sentative of patients needing short-term catheterisation in hospital, with particular emphasis on those individuals who were admitted for elective surgery (the population most often requiring this intervention) meaning that the results can be readily generalised. The wide spectrum of hospital types, specialties, and surgical procedures that we included was protective against selection bias but we did not recruit patients admitted directly to intensive care units and the number of eligible patients identifi ed and recruited from acute medical wards was small.
The trial had 90% power to detect a clinically meaningful benefi t from routine use of the antimicrobial catheters. For both comparisons, the central estimate was less than the eff ect size required and the 95% CI of the absolute risk diff erence included zero. The results therefore allow the fi rm conclusion that the silver alloy catheter and the nitrofural catheter did not diff er in terms of eff ectiveness from control. Assuming that our hypothesised eff ect size of 3·3% and CAUTI incidence with a standard catheter of 11% were correct, we had about 10% chance of a type II error (ie, to wrongly conclude that the catheters are ineff ective). Other investigations might have regarded a lesser absolute diff erence in CAUTI risk to be worth exploring and powered the study accordingly. However, we are confi dent that the 3·3% diff erence we set out to identify is a plausible estimate of the minimum benefi t needed to change routine practice.
To minimise misclassifi cation of participants' selfreport of urinary tract infection, we successfully resolved any missing data and confi rmed CAUTI through veri fi cation of clinician prescription of antibiotics. Because of the size of the trial and available resources, we could not independently verify that participants reporting no CAUTI after discharge from hospital had not received a prescription of antibiotic for urinary tract infection. We believe that misclassifi cation of absence of CAUTI was unlikely to diff er between trial groups because decisions by participants not to report symptoms and treatment decisions by primary care clinicians would not be infl uenced by the type of catheter used. Some episodes of community-acquired urinary tract infections were prob ably captured, especially for participants with short catheter duration. However recent catheterisation would remain a risk factor and there was no interaction between duration and eff ectiveness. Telephone and internet-based trial entry with computer-generated simple random isation reduced risk of allocation bias. Withdrawals after randomisation were mainly attrib utable to patients not receiving a catheter because of changes to treatment decisions or refusal to participate after unplanned catheterisation, which were factors unrelated to allocated catheter type. We could not mask the allocated catheter, but clinical staff who inserted the catheter were unlikely to be involved in decisions about timing of removal or prescription of antibiotics for CAUTI.
We used 10 000 cfu per mL or more as the threshold for a positive urine culture because this value is consistently reported by participating hospital laboratories. However, this cutoff might have resulted in higher absolute rates for microbiologically driven outcomes than is noted in studies that use the more common cutoff of 100 000 cfu 
Interpretation
The pragmatic design of our trial, large sample size, and use of primary outcomes combining perspectives from patients, clinicians, and health-care providers, provide clear information about the relative benefi t of two widely available antimicrobial catheters. Our fi nding that silver-alloy catheters and nitrofural-impregnated catheters do not provide the prestated minimum level of clinical eff ectiveness will allow better decisions to be made about use of these devices in health care.
per mL. We did not monitor use of other CAUTI prevention actions in participating hospitals, but noted no evidence for interaction between hospital and comparative eff ectiveness. This fi nding provides some reassurance that any possible diff erences between institutions or individual clinicians in terms of diagnosis of clinical CAUTI or criteria used to initiate antibiotic treatment did not aff ect our primary outcome. Duration of catheter use by most participants may have been too short to allow the antimicrobial eff ect of the tested catheters to become apparent. The study was designed to align with routine hospital practice, and patients in this setting are unlikely to be able to be stratifi ed as requiring diff erent short periods of catheterisation and receive diff erent catheters. We noted no signifi cant interaction between catheter duration and diff erences in incidence of CAUTI. The median duration seen in our trial was representative of current practice. 26 Our results provide no support for the routine use of silver alloy-coated catheters. The nitrofural catheter was not eff ective according to our prestated criteria and we would therefore regard our trial as showing no evidence to justify its use. However some individuals, particularly patients requiring short-term catheterisation, or providers seeking to reduce rates of health-care-acquired infections, might regard the low degree of benefi t suffi cient and be encouraged by our fi nding of signifi cance for secondary microbiological outcomes. However, we caution against such alternative conclusions because they are not supported by the primary trial result. Hospitals will need to carefully consider the lack of eff ectiveness of the tested catheters, taking into account diff erences between the UK NHS and their own healthcare system. Organisations that have already implemented use of silver-alloy catheters might be able to reallocate resources without loss of benefi t, whereas organisations planning their implementation might wish to reconsider. Overall, patients, clinicians, and health-care providers probably ought to persist with straightforward strategies to prevent CAUTI and await any adjustment of guidance on CAUTI prevention in the light of our results before making a decision. 1, 7, 22, 27 Contributors JN'D was the chief investigator of the study, had complete involvement and oversight of the study design, execution, and data collection, and was responsible for the fi nal report. RP contributed clinical expertise to the design of the study, supported conduct of the trial, interpreted the trial fi ndings and contributed to the report as fi rst author. TL contributed clinical expertise to the design of the study, helped with clinical support of the trial, and contributed to the report as joint fi rst author. GM led the statistical analysis of the study and writing up and display of the results. KS was responsible for the day-to-day management of the trial and also contributed to the report. MK did the health-related quality of life analysis. GMc designed the programming of the study database, data analysis, and contributed to writing the report. KG was responsible for the establishment of the trial and its initial day-to-day management. AM contributed to the design of the study and provided design support to the trial staff . KW led the microbiological aspects of trial design and planning, advised on conduct of the trial, and provided the microbiologist perspective for data interpretation and preparation of the report. BB contributed to the consumer aspect of the study and writing of the report. CG contributed to the design of the study and the writing of the report. CB did much of the statistical analysis required for the trial results. JB contributed to the delivery of the trial and to the writing of the report. JN was instrumental for the design of the study. LV contributed extensively to report writing. AG contributed to the overall study design and gave expert guidance on the fi nal report.
